AstraZeneca (LON:AZN)‘s stock had its “sell” rating restated by equities research analysts at UBS Group in a report issued on Wednesday, ThisIsMoney.Co.Uk reports. They presently have a GBX 5,700 ($74.48) target price on the biopharmaceutical company’s stock, up from their prior target price of GBX 5,400 ($70.56). UBS Group’s price target would suggest a potential downside of 21.16% from the stock’s current price.
A number of other equities analysts have also issued reports on the stock. Deutsche Bank reiterated a “buy” rating and issued a GBX 6,900 ($90.16) target price on shares of AstraZeneca in a research report on Friday, July 26th. Barclays set a GBX 7,600 ($99.31) target price on shares of AstraZeneca and gave the company a “buy” rating in a research report on Friday, August 9th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research report on Friday, August 9th. Citigroup reiterated a “buy” rating and issued a GBX 7,000 ($91.47) target price on shares of AstraZeneca in a research report on Monday, May 13th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research report on Monday. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company’s stock. AstraZeneca presently has a consensus rating of “Hold” and an average price target of GBX 6,688.24 ($87.39).
Shares of AZN opened at GBX 7,230 ($94.47) on Wednesday. The firm has a 50-day moving average price of GBX 6,755.80 and a 200 day moving average price of GBX 6,227.49. The firm has a market capitalization of $94.85 billion and a PE ratio of 42.23. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 144.48. AstraZeneca has a 52-week low of GBX 5,312 ($69.41) and a 52-week high of GBX 7,349.30 ($96.03).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.